{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:18:19Z","timestamp":1790788699202,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K43TW011421"],"award-info":[{"award-number":["K43TW011421"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI170426"],"award-info":[{"award-number":["U01AI170426"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI068634"],"award-info":[{"award-number":["AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI068636"],"award-info":[{"award-number":["AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI106701"],"award-info":[{"award-number":["AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI068632"],"award-info":[{"award-number":["U01 AI068632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["214321\/Z\/18\/Z"],"award-info":[{"award-number":["214321\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203135\/Z\/16\/Z"],"award-info":[{"award-number":["203135\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC2112"],"award-info":[{"award-number":["CC2112"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"South African Research Chairs Initiative of the Department of Science and Technology"},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["64787"],"award-info":[{"award-number":["64787"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010438","name":"Francis Crick Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2112"],"award-info":[{"award-number":["CC2112"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["CC2112"],"award-info":[{"award-number":["CC2112"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Centre of Imperial College NHS Trust"},{"name":"University of Cape Town Clinical PK Laboratory"},{"name":"Adult Clinical Trial Group"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Infant Maternal Pediatric Adolescent AIDS Clinical Trials Group"},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["AI068632"],"award-info":[{"award-number":["AI068632"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Several ongoing clinical trials are evaluating high-dose rifampicin (up to 35\u2005mg\/kg) for tuberculous meningitis (TBM). However, rifampicin pharmacokinetics at higher doses is not fully characterized, particularly in cerebrospinal fluid (CSF), the site of TBM disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a randomized controlled trial, adults with HIV-associated TBM were assigned to experimental arms of high-dose rifampicin (oral, 35\u2005mg\/kg; intravenous, 20\u2005mg\/kg) plus linezolid, with or without aspirin, or a control arm that received the standard of care with 10\u2005mg\/kg of oral rifampicin. Rifampicin concentrations, including the unbound fraction, were measured on plasma samples, and CSF was collected on days 3 and 28 of study enrollment. Data were analyzed by nonlinear mixed effects modeling.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 400 plasma and 44 CSF rifampicin concentrations from 48 participants were used for model development. The median (range) age and weight were 39 years (25\u201378) and 60 kg (30\u2013107). Rifampicin pharmacokinetics was best described by a 2-compartment disposition model with first-order transit oral absorption and elimination via saturable hepatic extraction. Typical clearance values for the standard dose for days 3 and 28 were 33.1 and 41.4 L\/h, respectively; high-dose values were 46.1 and 70.2 L\/h. The CSF-plasma ratio was approximately 6% and the equilibration half-life was 3.2\u2005hours. Simulated standard-dose rifampicin did not reach CSF concentrations above the critical concentration for Mycobacterium tuberculosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CSF penetration with standard-dose rifampicin is low. Our findings support continued evaluation of high-dose rifampicin for TBM treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf178","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T02:18:25Z","timestamp":1745893105000},"source":"Crossref","is-referenced-by-count":10,"title":["Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4907-345X","authenticated-orcid":false,"given":"Noha","family":"Abdelgawad","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-6719","authenticated-orcid":false,"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[{"name":"Wellcome Discovery Research Platforms for Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Observatory ,","place":["South Africa"]},{"name":"Institute for Infection and Immunity, City St George's University of London, London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9002-8087","authenticated-orcid":false,"given":"Kamunkhwala","family":"Gausi","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-5094","authenticated-orcid":false,"given":"Angharad","family":"Davis","sequence":"additional","affiliation":[{"name":"Wellcome Discovery Research Platforms for Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Observatory ,","place":["South Africa"]},{"name":"The Francis Crick Institute, London ,","place":["United Kingdom"]},{"name":"Queen Mary and Barts Tuberculosis Centre, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8813-0819","authenticated-orcid":false,"given":"Cari","family":"Stek","sequence":"additional","affiliation":[{"name":"Wellcome Discovery Research Platforms for Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Observatory ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9070-8699","authenticated-orcid":false,"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-4414","authenticated-orcid":false,"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[{"name":"Wellcome Discovery Research Platforms for Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Observatory ,","place":["South Africa"]},{"name":"Department of Medicine, University of Cape Town , Observatory ,","place":["South Africa"]},{"name":"Blizard Institute, Queen Mary University of London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-1800","authenticated-orcid":false,"given":"Robert J","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Wellcome Discovery Research Platforms for Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town , Observatory ,","place":["South Africa"]},{"name":"The Francis Crick Institute, London ,","place":["United Kingdom"]},{"name":"Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town , Observatory ,","place":["South Africa"]},{"name":"Department of Infectious Diseases, Imperial College London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-079X","authenticated-orcid":false,"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2025042822182101600_jiaf178-B1","doi-asserted-by":"crossref","first-page":"e0000069","DOI":"10.1371\/journal.pgph.0000069","article-title":"The global burden of tuberculous meningitis in adults: a modelling study","volume":"1","author":"Dodd","year":"2021","journal-title":"PLOS Glob Public Heal"},{"key":"2025042822182101600_jiaf178-B2","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/14656566.2019.1638912","article-title":"Key considerations in the pharmacotherapy of tuberculous meningitis","volume":"20","author":"Wasserman","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2025042822182101600_jiaf178-B3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4269\/ajtmh.19-0098","article-title":"Early mortality among immunocompetent patients of tuberculous meningitis: a prospective study","volume":"101","author":"Jaipuriar","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2025042822182101600_jiaf178-B4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/INF.0000000000000065","article-title":"Short intensified treatment in children with drug-susceptible tuberculous meningitis","volume":"33","author":"van Toorn","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2025042822182101600_jiaf178-B5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/cid\/ciy179","article-title":"Delayed sputum culture conversion in tuberculosis\u2013human immunodeficiency virus\u2013coinfected patients with low isoniazid and rifampicin concentrations","volume":"67","author":"Sekaggya-Wiltshire","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025042822182101600_jiaf178-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aau0965","article-title":"Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis","volume":"10","author":"Tucker","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025042822182101600_jiaf178-B7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/cid\/ciab162","article-title":"High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly human immunodeficiency virus (HIV)\u2013positive Ugandan adults: a phase II open-label randomized controlled trial","volume":"73","author":"Cresswell","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025042822182101600_jiaf178-B8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/10601330500371524","article-title":"Determination of absolute bioavailability of rifampicin by varying the mode of intravenous administration and the time of sampling","volume":"22","author":"Mariappan","year":"2005","journal-title":"Clin Res Regul Aff"},{"key":"2025042822182101600_jiaf178-B9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","article-title":"A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis","volume":"191","author":"Boeree","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042822182101600_jiaf178-B10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cpt.778","article-title":"A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses","volume":"103","author":"Svensson","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025042822182101600_jiaf178-B11","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/AAC.01830-15","article-title":"Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction","volume":"60","author":"Chirehwa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042822182101600_jiaf178-B12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","article-title":"Clinical pharmacokinetics of rifampicin","volume":"3","author":"Acocella","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"2025042822182101600_jiaf178-B13","doi-asserted-by":"crossref","first-page":"e0014021","DOI":"10.1128\/AAC.00140-21","article-title":"Plasma pharmacokinetics of high-dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial","volume":"65","author":"Wasserman","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042822182101600_jiaf178-B14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/cid\/ciac932","article-title":"A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus\u2013associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025042822182101600_jiaf178-B15","volume-title":"Statistical adjustment of data","author":"Deming","year":"1943"},{"key":"2025042822182101600_jiaf178-B16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/clinchem\/44.5.1024","article-title":"Performance of Deming regression analysis in case of misspecified analytical error ratio in method comparison studies","volume":"44","author":"Linnet","year":"1998","journal-title":"Clin Chem"},{"key":"2025042822182101600_jiaf178-B17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025042822182101600_jiaf178-B18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2025042822182101600_jiaf178-B19","doi-asserted-by":"crossref","first-page":"e00430-23","DOI":"10.1128\/aac.00430-23","article-title":"Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin","volume":"67","author":"Kengo","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042822182101600_jiaf178-B20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5588\/ijtld.17.0697","article-title":"Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications","volume":"22","author":"Court","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025042822182101600_jiaf178-B21","author":"World Health Organization"},{"key":"2025042822182101600_jiaf178-B22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/cpt.202","article-title":"Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children","volume":"98","author":"Savic","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2025042822182101600_jiaf178-B23","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/cid\/ciz1071","article-title":"Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials","volume":"71","author":"Svensson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025042822182101600_jiaf178-B24","doi-asserted-by":"crossref","first-page":"e00487-20","DOI":"10.1128\/AAC.00487-20","article-title":"Population pharmacokinetic properties of antituberculosis drugs in Vietnamese children with tuberculous meningitis","volume":"65","author":"Panjasawatwong","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042822182101600_jiaf178-B25","doi-asserted-by":"crossref","first-page":"e0147422","DOI":"10.1128\/aac.01474-22","article-title":"Population pharmacokinetic analysis of rifampicin in plasma, cerebrospinal fluid, and brain extracellular fluid in South African children with tuberculous meningitis","volume":"67","author":"Abdelgawad","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025042822182101600_jiaf178-B26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00558209","article-title":"Binding of rifampicin by human plasma proteins","volume":"7","author":"Boman","year":"1974","journal-title":"Eur J Clin Pharmacol"},{"key":"2025042822182101600_jiaf178-B27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/jac\/dky527","article-title":"Protein binding of rifampicin is not saturated when using high-dose rifampicin","volume":"74","author":"Litjens","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025042822182101600_jiaf178-B28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025042822182101600_jiaf178-B29","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf178\/63024724\/jiaf178.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf178\/63024724\/jiaf178.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T02:18:32Z","timestamp":1745893112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiaf178\/8121427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf178","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"article-number":"jiaf178"}}